TruSight Oncology 500 (TSO500) Comprehensive Assay
The TruSight Oncology 500 (TSO500) comprehensive assay employs a hybrid capture-based approach targeting 523 clinically relevant genes and leverages unique molecular indices to enable low frequency detection of SNVs, insertions, deletions, CNVs, gene fusions and transcript variants. This comprehensive cancer panel interrogates relevant cancer biomarkers with as little as 40 ng of DNA and RNA isolated from FFPE tissue with robust analytical performance. In addition to variant calls, the assay reports a tumor mutational burden (TMB) score and microsatellite instability (MSI) status. Q2 Solutions can meet your profiling needs by leveraging trusted technology from Illumina® and our expert support team in combination with Genomic Centers in the US, China, Edinburgh, and Singapore.